Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (31-40 of 144) with videos related to

Pageof 15
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|October 29, 2020
The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?Alberto Zambon, Alberto Mello E Silva, Michel Farnier
Presse Medicale (Paris, France : 1983)|April 13, 2013
[Diagnostic and treatment of familial hypercholesterolemia (FH) in adult: guidelines from the New French Society of Atherosclerosis (NSFA)]Michel Farnier, Eric Bruckert, Catherine Boileau, et al.
Archives of Cardiovascular Diseases|February 6, 2021
Triglycerides and risk of atherosclerotic cardiovascular disease: An updateMichel Farnier, Marianne Zeller, David Masson, et al.
Presse Medicale (Paris, France : 1983)|November 4, 2004
[Hypercholesterolemia, the future of drug associations]James Shepherd, Jean-Pierre Bassand, Hugues Milon, et al.
European Heart Journal. Acute Cardiovascular Care|November 19, 2016
A consensus statement on lipid management after acute coronary syndromeFrançois Schiele, Michel Farnier, Michel Krempf, et al.
International Journal of Cardiology|June 29, 2005
Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart diseaseMichel Farnier, Massimo Volpe, Rachid Massaad, et al.
Atherosclerosis|October 31, 2025
Not all fibrates are made equal: Learning from biology and clinical trialsAlberto Zambon, Bart Staels, Michel Farnier, et al.
Archives of Cardiovascular Diseases|December 19, 2022
Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE studyPatrick Henry, Bertrand Cariou, Michel Farnier, et al.
Journal of Lipid Research|August 2, 2008
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrateMichel Farnier, Inna Perevozskaya, William V Taggart, et al.
Journal of Clinical Lipidology|May 24, 2011
Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patientsMichel Farnier, William Taggart, Qian Dong, et al.
Pageof 15

Showing results (31-40 of 144) with videos related to

Sort By:
Pageof 15
European Heart Journal. Cardiovascular Pharmacotherapy|October 29, 2020
The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?Alberto Zambon, Alberto Mello E Silva, Michel Farnier
Presse Medicale (Paris, France : 1983)|April 13, 2013
[Diagnostic and treatment of familial hypercholesterolemia (FH) in adult: guidelines from the New French Society of Atherosclerosis (NSFA)]Michel Farnier, Eric Bruckert, Catherine Boileau, et al.
Archives of Cardiovascular Diseases|February 6, 2021
Triglycerides and risk of atherosclerotic cardiovascular disease: An updateMichel Farnier, Marianne Zeller, David Masson, et al.
Presse Medicale (Paris, France : 1983)|November 4, 2004
[Hypercholesterolemia, the future of drug associations]James Shepherd, Jean-Pierre Bassand, Hugues Milon, et al.
European Heart Journal. Acute Cardiovascular Care|November 19, 2016
A consensus statement on lipid management after acute coronary syndromeFrançois Schiele, Michel Farnier, Michel Krempf, et al.
International Journal of Cardiology|June 29, 2005
Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart diseaseMichel Farnier, Massimo Volpe, Rachid Massaad, et al.
Atherosclerosis|October 31, 2025
Not all fibrates are made equal: Learning from biology and clinical trialsAlberto Zambon, Bart Staels, Michel Farnier, et al.
Archives of Cardiovascular Diseases|December 19, 2022
Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE studyPatrick Henry, Bertrand Cariou, Michel Farnier, et al.
Journal of Lipid Research|August 2, 2008
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrateMichel Farnier, Inna Perevozskaya, William V Taggart, et al.
Journal of Clinical Lipidology|May 24, 2011
Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patientsMichel Farnier, William Taggart, Qian Dong, et al.
Pageof 15